Plus Therapeutics Inc (PSTV) - Net Assets
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has net assets worth $5.05 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.67 Million) and total liabilities ($13.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Plus Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $5.05 Million |
| % of Total Assets | 27.07% |
| Annual Growth Rate | N/A |
| 5-Year Change | -395.25% |
| 10-Year Change | -173.32% |
| Growth Volatility | 1323.62 |
Plus Therapeutics Inc - Net Assets Trend (1998–2024)
This chart illustrates how Plus Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Plus Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Net Assets for Plus Therapeutics Inc (1998–2024)
The table below shows the annual net assets of Plus Therapeutics Inc from 1998 to 2024. For live valuation and market cap data, see Plus Therapeutics Inc (PSTV) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-8.95 Million | -563.87% |
| 2023-12-31 | $-1.35 Million | -120.92% |
| 2022-12-31 | $6.45 Million | -40.52% |
| 2021-12-31 | $10.84 Million | +257.51% |
| 2020-12-31 | $3.03 Million | +161.29% |
| 2019-12-31 | $1.16 Million | -77.80% |
| 2018-12-31 | $5.22 Million | -59.81% |
| 2017-12-31 | $13.00 Million | +18.33% |
| 2016-12-31 | $10.99 Million | -10.00% |
| 2015-12-31 | $12.21 Million | +314.07% |
| 2014-12-31 | $-5.70 Million | -282.06% |
| 2013-12-31 | $3.13 Million | -51.48% |
| 2012-12-31 | $6.46 Million | -35.10% |
| 2011-12-31 | $9.95 Million | -56.52% |
| 2010-12-31 | $22.87 Million | +725.29% |
| 2009-12-31 | $-3.66 Million | +52.60% |
| 2008-12-31 | $-7.72 Million | +17.90% |
| 2007-12-31 | $-9.40 Million | +13.07% |
| 2006-12-31 | $-10.81 Million | -73.59% |
| 2005-12-31 | $-6.23 Million | -148.54% |
| 2004-12-31 | $12.83 Million | -13.92% |
| 2003-12-31 | $14.91 Million | -42.65% |
| 2002-12-31 | $26.00 Million | -32.46% |
| 2001-12-31 | $38.49 Million | -21.99% |
| 2000-12-31 | $49.34 Million | +902.59% |
| 1999-12-31 | $-6.15 Million | -5791.67% |
| 1998-12-31 | $108.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Plus Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49347900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | % |
| Other Components | $484.52 Million | % |
| Total Equity | $-8.95 Million | 100.00% |
Plus Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Plus Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dr. Hönle AG
F:HNL
|
$52.66 Million |
|
Power Metals Corp
V:PWM
|
$52.67 Million |
|
Sam Jung Pulp
KO:009770
|
$52.69 Million |
|
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
|
$52.70 Million |
|
BranchOut Food Inc. Common Stock
NASDAQ:BOF
|
$52.64 Million |
|
Toivo Group Oyj
HE:TOIVO
|
$52.62 Million |
|
Voksel Electric Tbk
JK:VOKS
|
$52.60 Million |
|
Adisyn Ltd
AU:AI1
|
$52.55 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Plus Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,348,000 to -8,949,000, a change of -7,601,000.
- Net loss of 12,978,000 reduced equity.
- Share repurchases of 374,000 reduced equity.
- New share issuances of 7,265,000 increased equity.
- Other factors decreased equity by 1,514,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.98 Million | -145.02% |
| Share Repurchases | $374.00K | -4.18% |
| Share Issuances | $7.26 Million | +81.18% |
| Other Changes | $-1.51 Million | -16.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Plus Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1998-12-31 | $0.77 | $6.09 | x |
| 1999-12-31 | $-43.91 | $6.09 | x |
| 2000-12-31 | $429000.00 | $6.09 | x |
| 2001-12-31 | $272.95 | $6.09 | x |
| 2002-12-31 | $192.56 | $6.09 | x |
| 2003-12-31 | $114.68 | $6.09 | x |
| 2004-12-31 | $98.72 | $6.09 | x |
| 2005-12-31 | $-43.56 | $6.09 | x |
| 2006-12-31 | $-62.14 | $6.09 | x |
| 2007-12-31 | $-41.96 | $6.09 | x |
| 2008-12-31 | $-28.27 | $6.09 | x |
| 2009-12-31 | $-9.81 | $6.09 | x |
| 2010-12-31 | $47.16 | $6.09 | x |
| 2011-12-31 | $18.84 | $6.09 | x |
| 2012-12-31 | $12365.90 | $6.09 | x |
| 2013-12-31 | $5194.03 | $6.09 | x |
| 2014-12-31 | $-7930.46 | $6.09 | x |
| 2015-12-31 | $9756.99 | $6.09 | x |
| 2016-12-31 | $4766.16 | $6.09 | x |
| 2017-12-31 | $30.10 | $6.09 | x |
| 2018-12-31 | $450.82 | $6.09 | x |
| 2019-12-31 | $12.57 | $6.09 | x |
| 2020-12-31 | $10.27 | $6.09 | x |
| 2021-12-31 | $13.45 | $6.09 | x |
| 2022-12-31 | $3.68 | $6.09 | x |
| 2023-12-31 | $-0.43 | $6.09 | x |
| 2024-12-31 | $-1.16 | $6.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Plus Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -222.84%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-233.78%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1998 | -1935.19% | 0.00% | 0.00x | 9.44x | $-2.10 Million |
| 1999 | 0.00% | -302.12% | 0.27x | 0.00x | $-3.96 Million |
| 2000 | -17.52% | -138.30% | 0.12x | 1.06x | $-13.58 Million |
| 2001 | -29.12% | -198.42% | 0.13x | 1.12x | $-15.06 Million |
| 2002 | -50.02% | -141.86% | 0.23x | 1.51x | $-15.60 Million |
| 2003 | -62.26% | -65.89% | 0.50x | 1.88x | $-10.77 Million |
| 2004 | -16.29% | -30.65% | 0.27x | 1.98x | $-3.37 Million |
| 2005 | 0.00% | -441.93% | 0.21x | 0.00x | $-25.92 Million |
| 2006 | 0.00% | -321.02% | 0.32x | 0.00x | $-24.37 Million |
| 2007 | 0.00% | -474.00% | 0.28x | 0.00x | $-27.73 Million |
| 2008 | 0.00% | -438.29% | 0.27x | 0.00x | $-29.26 Million |
| 2009 | 0.00% | -157.61% | 0.60x | 0.00x | $-22.85 Million |
| 2010 | -120.20% | -258.72% | 0.16x | 2.90x | $-29.78 Million |
| 2011 | -326.27% | -324.64% | 0.19x | 5.18x | $-33.45 Million |
| 2012 | -500.06% | -222.60% | 0.34x | 6.70x | $-32.92 Million |
| 2013 | -835.79% | -214.64% | 0.29x | 13.43x | $-26.49 Million |
| 2014 | 0.00% | -491.81% | 0.20x | 0.00x | $-36.80 Million |
| 2015 | -153.56% | -160.77% | 0.31x | 3.09x | $-19.96 Million |
| 2016 | -200.67% | -193.73% | 0.33x | 3.15x | $-23.14 Million |
| 2017 | -174.51% | -353.86% | 0.20x | 2.43x | $-23.99 Million |
| 2018 | -241.80% | -423.53% | 0.12x | 4.59x | $-13.16 Million |
| 2019 | -938.53% | -155.57% | 0.30x | 20.03x | $-11.00 Million |
| 2020 | -271.89% | -2719.80% | 0.03x | 3.99x | $-8.54 Million |
| 2021 | -123.65% | 0.00% | 0.00x | 2.03x | $-14.48 Million |
| 2022 | -314.58% | -9051.34% | 0.01x | 3.70x | $-20.92 Million |
| 2023 | 0.00% | -271.04% | 0.43x | 0.00x | $-13.18 Million |
| 2024 | 0.00% | -222.84% | 0.88x | 0.00x | $-12.08 Million |
Industry Comparison
This section compares Plus Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Plus Therapeutics Inc (PSTV) | $5.05 Million | -1935.19% | 2.69x | $52.66 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers… Read more